KPV: A Promising Anti-Inflammatory Tripeptide With No Human Trials

KPV is one of the more scientifically interesting peptides on the wellness market. It is a tiny piece of a natural hormone that, in lab and animal studies, calms inflammation strongly while skipping the parent hormone’s other effects. The catch is the same one that trails most gray-market peptides (compounds sold without regulatory approval): there are no human trials.

What it is

KPV is a short, straight chain of just three amino acids (the building blocks of proteins) — lysine, proline, and valine — linked together. That little sequence is the tail end (the C-terminal, meaning the back of the chain; specifically positions 11 to 13) of a hormone called alpha-melanocyte-stimulating hormone, or alpha-MSH. Alpha-MSH is a 13-amino-acid hormone that your body makes by snipping it out of a larger parent protein known as POMC.

What makes KPV stand out is what it does not include. The part of alpha-MSH that darkens skin pigment and locks onto cell receptors lives in a different stretch of the molecule (a sequence written as His-Phe-Arg-Trp). KPV does not contain that stretch, yet researchers found it keeps most of alpha-MSH’s power to quiet inflammation. In plain terms, it seems to keep the “calm inflammation” job while dropping the “change skin color” job.

You will see it sold as “KPV (free base)” or “KPV acetate” by gray-market vendors, labeled as a research chemical. It is not a dietary supplement, and it is not an approved drug.

The claims

In legitimate research, KPV has been studied for inflammation in the gut and inflammatory bowel disease (colitis, meaning inflammation of the colon), for skin inflammation such as contact dermatitis (an itchy rash from something touching the skin), for wound healing, and for tamping down inflammation driven by a master switch called NF-kappaB. It has also been tested as a passenger molecule inside systems designed to deliver drugs straight to the gut.

The marketing goes much further than that. Vendor and clinic pages pitch KPV for “gut healing” and “leaky gut repair,” for skin and anti-aging benefits, for calming mast cells (immune cells that release histamine), for allergy and histamine control, for fighting infection in wounds, and for whole-body anti-inflammatory recovery. Some sites describe it as something that switches on melanocortin receptors (the MC1R or MC3R receptors). That description overstates the science: the core research on KPV’s gut effects points to a mechanism that works without needing those receptors, not by switching them on. One more thing worth flagging — most of the consumer-facing “evidence” pages are written by sellers, compounding clinics, or peptide-vendor blogs, not by independent sources.

What the evidence actually shows

There are no published human trials of KPV. There are no registered ClinicalTrials.gov studies, and no peer-reviewed data on how well it works or how safe it is in people — by any route, whether swallowed, injected, or applied to the skin. Every claim about what KPV does in humans is borrowed from animal studies and lab-dish (cell-culture) work.

That said, the preclinical research is genuinely substantial and stretches across roughly two decades.

The big mechanism discoveries came in 2008. Dalmasso and colleagues (writing in Gastroenterology) showed that KPV gets carried into gut and immune cells by a transporter (a kind of molecular doorway) called PepT1 — which happens to be more active in an inflamed colon — and that at very low concentrations (around 10 nM, or nanomolar, in cell studies) it shuts down the NF-kappaB and MAP-kinase signaling pathways and lowers inflammatory messenger molecules called cytokines. Oral KPV reduced how severe colitis was in two different mouse models. That same year, Kannengiesser and colleagues (in Inflammatory Bowel Disease) reported that KPV cut down the rush of inflammatory cells into tissue, reduced tissue damage, helped mice regain weight, and saved mice that lacked the melanocortin-1 receptor from otherwise-fatal colitis — strong evidence that the benefit does not depend on that receptor.

Earlier still, Getting and colleagues (in the Journal of Pharmacology and Experimental Therapeutics, 2003) showed that KPV reduced the buildup of immune cells in mouse models of peritonitis (inflammation of the abdominal lining), behaved differently from the core MSH peptides, and stayed active even in mice whose MC1R receptor did not work — pointing to an effect driven by blocking a signaling molecule called interleukin-1-beta rather than by the melanocortin receptors. A 2010 review by Brzoska and colleagues summed up the central finding: KPV holds onto its anti-inflammatory activity without carrying the receptor-binding part of the molecule. The whole line of research traces back to Hiltz and Lipton in 1989, who were the first to show that the C-terminal tripeptide region carries anti-inflammatory activity all on its own.

More recent work has been about how to deliver KPV rather than finding new clinical uses. For example, one study packed KPV into hyaluronic-acid-coated nanoparticles (tiny carrier particles) so it could be swallowed and delivered to the inflamed gut (Xiao and colleagues, 2017), and another looked at pushing KPV through tiny holes made in human skin using iontophoresis (a mild electric current that drives a drug through skin) (Pawar and colleagues, 2017). That second study is a delivery-and-absorption experiment — it does not test whether KPV actually treats anything in people.

A few honest cautions about the animal data: the colitis in these studies is triggered with chemicals, which is an imperfect stand-in for human IBD; the results are mostly measured by looking at tissue under a microscope; and the work clusters around just a handful of academic groups. What is missing is everything you would need to judge real human use — how the body absorbs and clears it (pharmacokinetics), the right dose, controlled data on whether it works and is safe, whether it stays stable when swallowed by humans, and long-term toxicity testing.

Safety

There is essentially no published human safety data. No controlled human safety dataset exists for KPV by any route.

In rodent studies, KPV was generally well tolerated, with anti-inflammatory benefit and no obvious organ damage at the doses tested. But those were studies of whether it works, not formal safety (toxicology) studies, and they were not built to catch rare or long-term harms.

Be skeptical of side-effect numbers that sound precise. Some vendor and clinic pages quote figures like “injection-site reactions in 8 to 12 percent” or “nausea in 3 to 5 percent.” Those numbers have no traceable peer-reviewed human source and should not be treated as real data. The honest answer is that human safety is simply unknown. On top of that, a gray-market product carries the usual risks of unregulated peptides: questionable purity and sterility, possible contamination with endotoxin (a bacterial byproduct that can cause fever and other reactions), and mislabeling.

Legal and regulatory status

A few separate facts tend to get tangled together here, so let’s take them one at a time.

KPV is not approved by the FDA for any use, and it is not a recognized dietary ingredient. It is sold gray-market as a research chemical.

Right now it sits in the FDA’s 503A Category 2 — a list of bulk drug substances that have too little safety data, which means they are not eligible for the leeway that would otherwise let compounding pharmacies make them. That label dates back to the FDA’s September 2023 action on nominated peptides, not to anything in 2026.

In April 2026, the FDA published a Federal Register notice (docket FDA-2025-N-6895) scheduling a Pharmacy Compounding Advisory Committee meeting for July 23–24, 2026. KPV is on the July 23 agenda alongside BPC-157, TB-500, and MOTS-C. Two things matter here: the committee’s recommendations are non-binding, and simply being on the agenda does not authorize compounding or imply approval. Any move to allow compounding would still require formal rulemaking. (This section is current as of June 2026 and is a moving target.)

No marketing authorization for KPV has been identified in any major country abroad.

On anti-doping: KPV is not a named substance on the WADA Prohibited List for 2025 or 2026. It does not switch on melanocortin receptors and has no documented performance-enhancing effect. Even so, not being on the named list is not a full all-clear, because WADA uses catch-all wording that covers substances with a similar structure or biological effect.

Bottom line

KPV has an unusually clean scientific story for a gray-market peptide: a well-understood mechanism, repeatable anti-inflammatory effects in animals, and a clear reason why it might calm inflammation without alpha-MSH’s other actions. But “promising in mice” is not the same as “proven in people.” There are no human trials, no human safety data, and no approved product. The marketing claims about gut healing, anti-aging, and recovery run far ahead of the evidence. Treat KPV as an interesting hypothesis, not an established treatment. This is not medical advice.

Evidence grade: 3/10 · Animal only.

Sources

• PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation (Dalmasso et al., Gastroenterology 2008)
• Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of IBD (Kannengiesser et al., Inflamm Bowel Dis 2008)
• Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-MSH peptides (Getting et al., JPET 2003)
• Anti-inflammatory effects of alpha-MSH related peptides beyond the pharmacophore (Brzoska et al., Adv Exp Med Biol 2010)
• Antiinflammatory activity of a COOH-terminal fragment of alpha-MSH (Hiltz & Lipton, FASEB J 1989)
• HA-functionalized KPV-loaded nanoparticles for oral delivery in ulcerative colitis (Xiao et al., Molecular Therapy 2017)
• Transdermal iontophoretic delivery of KPV across microporated human skin (Pawar et al., J Pharm Sci 2017)
• Alpha-MSH and related peptides: antimicrobial and anti-inflammatory review (Singh & Mukhopadhyay, BioMed Res Int 2014)
• The melanocortin system in inflammatory bowel disease (Gravina et al., Cells 2023)
• July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (FDA)
• Pharmacy Compounding Advisory Committee Notice of Meeting (Federal Register, docket FDA-2025-N-6895)
• Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (FDA)
• WADA’s 2026 Prohibited List now in force (World Anti-Doping Agency)